Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes
Objective. To compare the effect of the rapid-acting insulin analogues (RAIAs) aspart (NovoRapid) and lispro (Prandilin) on glycemic variations by continuous glucose monitoring system (CGMS) in patients within newly diagnosed type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2018/2087960 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554423773036544 |
|---|---|
| author | Bing-li Liu Guo-ping Yin Feng-fei Li Yun Hu Jin-dan Wu Mao-yuan Chen Lei Ye Xiao-fei Su Jian-hua Ma |
| author_facet | Bing-li Liu Guo-ping Yin Feng-fei Li Yun Hu Jin-dan Wu Mao-yuan Chen Lei Ye Xiao-fei Su Jian-hua Ma |
| author_sort | Bing-li Liu |
| collection | DOAJ |
| description | Objective. To compare the effect of the rapid-acting insulin analogues (RAIAs) aspart (NovoRapid) and lispro (Prandilin) on glycemic variations by continuous glucose monitoring system (CGMS) in patients within newly diagnosed type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin infusion (CSII) and metformin intensive therapy. Methods. This is a single-blind randomized controlled trial. A total of 110 patients with newly diagnosed T2DM and with hemoglobin A1c (HbA1c%) above 9% was hospitalized and randomly divided into two groups: group Asp (NovoRapid group) and group Lis (Prandilin group). They all received CSII and metformin therapy. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. C-peptide and insulin and fructosamine were determined. CGMS was continuously applied for 4 days after reaching the glycemic target. Results. There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis. No significant differences were seen in the 24 h mean amplitude of glycemic excursions (MAGE), 24 h mean blood glucose (MBG), the standard deviation of the MBG (SDBG), fasting blood glucose, number of glycemic excursion (NGE), and the incidence of hypoglycemia between the two groups. Similarly, no significant differences were found in areas under the curve (AUC) of glucose above 10.0 mmol/L or the decremental area over the curve (AOC) of glucose below 3.9 mmol/L between the two groups. Conclusions. Lispro and aspart had the similar ability to control the glycemic variations in patients with newly diagnosed T2DM. This study was registered with ClinicalTrials.gov, number ChiCTR-IPR-17010338. |
| format | Article |
| id | doaj-art-6bb938eb94ab4fcdaa9a123aed5735c2 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-6bb938eb94ab4fcdaa9a123aed5735c22025-02-03T05:51:37ZengWileyInternational Journal of Endocrinology1687-83371687-83452018-01-01201810.1155/2018/20879602087960Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 DiabetesBing-li Liu0Guo-ping Yin1Feng-fei Li2Yun Hu3Jin-dan Wu4Mao-yuan Chen5Lei Ye6Xiao-fei Su7Jian-hua Ma8Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaNational Heart Centre Singapore, National Heart Research Institute Singapore, SingaporeDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaObjective. To compare the effect of the rapid-acting insulin analogues (RAIAs) aspart (NovoRapid) and lispro (Prandilin) on glycemic variations by continuous glucose monitoring system (CGMS) in patients within newly diagnosed type 2 diabetes mellitus (T2DM) receiving continuous subcutaneous insulin infusion (CSII) and metformin intensive therapy. Methods. This is a single-blind randomized controlled trial. A total of 110 patients with newly diagnosed T2DM and with hemoglobin A1c (HbA1c%) above 9% was hospitalized and randomly divided into two groups: group Asp (NovoRapid group) and group Lis (Prandilin group). They all received CSII and metformin therapy. Treatments were maintained for 2-3 weeks after the glycaemic target was reached. C-peptide and insulin and fructosamine were determined. CGMS was continuously applied for 4 days after reaching the glycemic target. Results. There were no significant differences in daily dosages of insulin, fasting plasma C-P and 2 h postprandial C-P and insulin, and fructosamine at the baseline and endpoint between the groups Asp and Lis. No significant differences were seen in the 24 h mean amplitude of glycemic excursions (MAGE), 24 h mean blood glucose (MBG), the standard deviation of the MBG (SDBG), fasting blood glucose, number of glycemic excursion (NGE), and the incidence of hypoglycemia between the two groups. Similarly, no significant differences were found in areas under the curve (AUC) of glucose above 10.0 mmol/L or the decremental area over the curve (AOC) of glucose below 3.9 mmol/L between the two groups. Conclusions. Lispro and aspart had the similar ability to control the glycemic variations in patients with newly diagnosed T2DM. This study was registered with ClinicalTrials.gov, number ChiCTR-IPR-17010338.http://dx.doi.org/10.1155/2018/2087960 |
| spellingShingle | Bing-li Liu Guo-ping Yin Feng-fei Li Yun Hu Jin-dan Wu Mao-yuan Chen Lei Ye Xiao-fei Su Jian-hua Ma Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes International Journal of Endocrinology |
| title | Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes |
| title_full | Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes |
| title_fullStr | Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes |
| title_full_unstemmed | Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes |
| title_short | Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes |
| title_sort | comparison of efficacy and safety of lispro and aspart evaluated by continuous glucose monitoring system in patients with newly diagnosed type 2 diabetes |
| url | http://dx.doi.org/10.1155/2018/2087960 |
| work_keys_str_mv | AT bingliliu comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT guopingyin comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT fengfeili comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT yunhu comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT jindanwu comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT maoyuanchen comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT leiye comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT xiaofeisu comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes AT jianhuama comparisonofefficacyandsafetyoflisproandaspartevaluatedbycontinuousglucosemonitoringsysteminpatientswithnewlydiagnosedtype2diabetes |